Cingulate Manufactures Clinical Supply, Pediatric Phase 3 ADHD Studies July and August

  Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has successfully manufactured the clinical supply for upcoming pivotal Phase 3 trials of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of attention deficit/hyperactivity disorder (ADHD). All doses of CTx-1301 are now available for both pivotal Phase 3 pediatric and adolescent clinical trials, with the fixed-dose study scheduled to begin the week of July 24.

https://www.biospace.com/article/releases/cingulate-successfully-manufactures-clinical-supply-initiation-of-pediatric-phase-3-studies-to-commence-in-july-and-augustannouncement-confirms-cingulate-on-track-with-development-and-regulatory-milestones/